{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T15:37:24Z","timestamp":1791992244174,"version":"4.4.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1007\/s40265-024-02060-1","type":"journal-article","created":{"date-parts":[[2024,7,5]],"date-time":"2024-07-05T09:02:07Z","timestamp":1720170127000},"page":"867-874","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Nogapendekin alfa Inbakicept: First Approval"],"prefix":"10.1007","volume":"84","author":[{"given":"Susan J.","family":"Keam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,5]]},"reference":[{"issue":"12","key":"2060_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cells12121611","volume":"12","author":"G Lui","year":"2023","unstructured":"Lui G, Minnar CM, Soon-Shiong P, et al. Exploiting an interleukin-15 heterodimeric agonist (N803) for effective immunotherapy of solid malignancies. Cells. 2023;12(12):1\u201315.","journal-title":"Cells"},{"key":"2060_CR2","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.cyto.2017.12.003","volume":"107","author":"B Liu","year":"2018","unstructured":"Liu B, Jones M, Kong L, et al. Evaluation of the biological activities of the IL-15 superagonist complex, ALT-803, following intravenous versus subcutaneous administration in murine models. Cytokine. 2018;107:105\u201312.","journal-title":"Cytokine"},{"issue":"1","key":"2060_CR3","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1158\/2326-6066.CIR-15-0093-T","volume":"4","author":"PR Rhode","year":"2016","unstructured":"Rhode PR, Egan JO, Xu W, et al. Comparison of the superagonist complex, ALT-803, to IL15 as cancer immunotherapeutics in animal models. Cancer Immunol Res. 2016;4(1):49\u201360.","journal-title":"Cancer Immunol Res"},{"issue":"6","key":"2060_CR4","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.4049\/jimmunol.2100066","volume":"208","author":"MP Rubinstein","year":"2022","unstructured":"Rubinstein MP, Williams C, Mart C, et al. Phase I trial characterizing the pharmacokinetic profile of N-803, a chimeric IL-15 superagonist, in healthy volunteers. J Immunol. 2022;208(6):1362\u201370.","journal-title":"J Immunol"},{"key":"2060_CR5","unstructured":"Altor BioScience LLC. Nogapendekin alfa inbakicept-pmln: US prescribing information. 2024. https:\/\/anktiva.com\/. Accessed 22 May 2024."},{"key":"2060_CR6","doi-asserted-by":"publisher","first-page":"1040669","DOI":"10.3389\/fimmu.2022.1040669","volume":"13","author":"W Chen","year":"2022","unstructured":"Chen W, Liu N, Yuan Y, et al. ALT-803 in the treatment of non-muscle-invasive bladder cancer: preclinical and clinical evidence and translational potential. Front Immunol. 2022;13:1040669.","journal-title":"Front Immunol"},{"key":"2060_CR7","unstructured":"ImmunityBio Inc. Annual Filings Report. 2024. https:\/\/ir.immunitybio.com\/. Accessed 1 May 2024."},{"key":"2060_CR8","unstructured":"ImmunityBio Inc. ImmunityBio announces FDA approval of ANKTIVA\u00ae, first-in-class IL-15 receptor agonist for BCG-unresponsive non-muscle invasive bladder cancer [media release].  22 Apr 2024. https:\/\/immunitybio.com\/."},{"key":"2060_CR9","unstructured":"US Food & Drug Administration. FDA approves nogapendekin alfa inbakicept-pmln for BCG-unresponsive non-muscle invasive bladder cancer [media release].  22 Apr 2024. https:\/\/www.fda.gov\/."},{"key":"2060_CR10","unstructured":"ImmunityBio Inc., NantKwest Inc. ImmunityBio and NantKwest complete merger [media release].  9 Mar 2021. https:\/\/immunitybio.com\/."},{"key":"2060_CR11","unstructured":"Altor BioScience Corporation. Altor BioScience Corporation and NantKwest Inc. announce co-development agreement to advance innovative natural killer cell combination iImmunotherapies for the treatment of cancer [media release].  4 Oct 2016. https:\/\/immunitybio.com\/."},{"issue":"6","key":"2060_CR12","doi-asserted-by":"publisher","first-page":"e96705","DOI":"10.1371\/journal.pone.0096705","volume":"9","author":"E Gomes-Giacoia","year":"2014","unstructured":"Gomes-Giacoia E, Miyake M, Goodison S, et al. Intravesical ALT-803 and BCG treatment reduces tumor burden in a carcinogen induced bladder cancer rat model; a role for cytokine production and NK cell expansion. PLoS ONE. 2014;9(6):e96705.","journal-title":"PLoS ONE"},{"issue":"1","key":"2060_CR13","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s12967-019-1778-6","volume":"17","author":"H Furuya","year":"2019","unstructured":"Furuya H, Chan OTM, Pagano I, et al. Effectiveness of two different dose administration regimens of an IL-15 superagonist complex (ALT-803) in an orthotopic bladder cancer mouse model. J Transl Med. 2019;17(1):29.","journal-title":"J Transl Med"},{"issue":"1","key":"2060_CR14","doi-asserted-by":"publisher","first-page":"814","DOI":"10.18632\/oncotarget.6416","volume":"7","author":"F Basher","year":"2016","unstructured":"Basher F, Jeng EK, Wong H, et al. Cooperative therapeutic anti-tumor effect of IL-15 agonist ALT-803 and co-targeting soluble NKG2D ligand sMIC. Oncotarget. 2016;7(1):814\u201330.","journal-title":"Oncotarget"},{"issue":"7","key":"2060_CR15","doi-asserted-by":"publisher","first-page":"e002267","DOI":"10.1136\/jitc-2020-002267","volume":"9","author":"Y Chu","year":"2021","unstructured":"Chu Y, Nayyar G, Jiang S, et al. Combinatorial immunotherapy of N-803 (IL-15 superagonist) and dinutuximab with ex vivo expanded natural killer cells significantly enhances in vitro cytotoxicity against GD2(+) pediatric solid tumors and in vivo survival of xenografted immunodeficient NSG mice. J Immunother Cancer. 2021;9(7):e002267.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"2060_CR16","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1002\/ijc.29686","volume":"138","author":"D Mathios","year":"2016","unstructured":"Mathios D, Park CK, Marcus WD, et al. Therapeutic administration of IL-15 superagonist complex ALT-803 leads to long-term survival and durable antitumor immune response in a murine glioblastoma model. Int J Cancer. 2016;138(1):187\u201394.","journal-title":"Int J Cancer"},{"issue":"8","key":"2060_CR17","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1007\/s00262-019-02372-2","volume":"68","author":"A Pinette","year":"2019","unstructured":"Pinette A, McMichael E, Courtney NB, et al. An IL-15-based superagonist ALT-803 enhances the NK cell response to cetuximab-treated squamous cell carcinoma of the head and neck. Cancer Immunol Immunother. 2019;68(8):1379\u201389.","journal-title":"Cancer Immunol Immunother"},{"issue":"5","key":"2060_CR18","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1007\/s00262-020-02749-8","volume":"70","author":"JMR Van der Meer","year":"2021","unstructured":"Van der Meer JMR, Maas RJA, Guldevall K, et al. IL-15 superagonist N-803 improves IFN\u03b3 production and killing of leukemia and ovarian cancer cells by CD34+ progenitor-derived NK cells. Cancer Immunol Immunother. 2021;70(5):1305\u201321.","journal-title":"Cancer Immunol Immunother"},{"issue":"2","key":"2060_CR19","first-page":"612","volume":"9","author":"N Toney","year":"2021","unstructured":"Toney N, Tsai YT, Redman J, et al. Immune correlates from QuEST1 in men with castration-resistant prostate cancer [abstract no. 582]. J Immunother Cancer. 2021;9(2):612.","journal-title":"J Immunother Cancer"},{"issue":"2","key":"2060_CR20","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1038\/s41591-021-01651-9","volume":"28","author":"JS Miller","year":"2022","unstructured":"Miller JS, Davis ZB, Helgeson E, et al. Safety and virologic impact of the IL-15 superagonist N-803 in people living with HIV: a phase 1 trial. Nat Med. 2022;28(2):392\u2013400.","journal-title":"Nat Med"},{"issue":"1","key":"2060_CR21","doi-asserted-by":"publisher","first-page":"EVIDoa2200167","DOI":"10.1056\/EVIDoa2200167","volume":"2","author":"K Chamie","year":"2023","unstructured":"Chamie K, Chang SS, Kramolowsky E, et al. IL-15 superagonist NAI in BCG-unresponsive non-muscle-invasive bladder cancer. NEJM Evid. 2023;2(1):EVIDoa2200167.","journal-title":"NEJM Evid."},{"issue":"1","key":"2060_CR22","doi-asserted-by":"publisher","first-page":"1912885","DOI":"10.1080\/2162402X.2021.1912885","volume":"10","author":"CJ Rosser","year":"2021","unstructured":"Rosser CJ, Tikhonenkov S, Nix JW, et al. Safety, tolerability, and long-term clinical outcomes of an IL-15 analogue (N-803) admixed with Bacillus Calmette-Gu\u00e9rin (BCG) for the treatment of bladder cancer. Oncoimmunology. 2021;10(1):1912885.","journal-title":"Oncoimmunology"},{"key":"2060_CR23","unstructured":"ImmunityBio Inc. ANKTIVA synergizes with T cell activity of BCG in both the na\u00efve and unresponsive setting by activating NK cells, interferon gamma, and driving memory CD8+ killer T cells. 2024. https:\/\/immunitybio.com\/wp-content\/uploads\/2024\/05\/ANKTIVA-BCG-Naive.pdf. Accessed 15 May 2024."},{"key":"2060_CR24","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1200\/JCO.2021.39.15_suppl.2596","volume":"39","author":"JM Wrangle","year":"2021","unstructured":"Wrangle JM, Awad MM, Badin FB, et al. Preliminary data from QUILT 3.055: a phase 2 multi-cohort study of N803 (IL-15 superagonist) in combination with checkpoint inhibitors (CPI) [abstract no. 2596]. J Clin Oncol. 2021;39:15.","journal-title":"J Clin Oncol"},{"key":"2060_CR25","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1200\/JCO.2023.41.4_suppl.720","volume":"41","author":"TE Seery","year":"2023","unstructured":"Seery TE, Nangia CS, Reid PD, et al. Overall survival in patients with metastatic or locally advanced pancreatic cancer following chemoradiation with novel combination of aldoxorubicin, N-803 IL-15 superagonist, and PDL1-NK cell therapy [abstract no. 720]. J Clin Oncol. 2023;41:4.","journal-title":"J Clin Oncol"},{"issue":"4 Suppl","key":"2060_CR26","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1200\/JCO.2023.41.4_suppl.116","volume":"41","author":"DM Pastor","year":"2023","unstructured":"Pastor DM, Redman JM, Floudas CS, et al. Phase II evaluation of combination immunotherapy with CV301, N-803, bintrafusp alfa, and M9241 in patients with advanced small bowel and colorectal cancers [abstract no. 116]. J Clin Oncol. 2023;41(4 Suppl):116.","journal-title":"J Clin Oncol"},{"issue":"Suppl 4","key":"2060_CR27","doi-asserted-by":"publisher","first-page":"S511","DOI":"10.1016\/j.annonc.2020.08.875","volume":"31","author":"JM Redman","year":"2020","unstructured":"Redman JM, Madan RA, Karzai F, et al. Efficacy of BN-brachyury (BNVax) plus bintrafusp alfa (BA) + N-803 in castration-resistant prostate cancer (CRPC): results from a preliminary analysis of the Quick Efficacy Seeking Trial (QuEST1) [abstract no. 616MO]. Ann Oncol. 2020;31(Suppl 4):S511.","journal-title":"Ann Oncol"},{"key":"2060_CR28","unstructured":"ImmunityBio Inc. ImmunityBio pipeline. 2024. https:\/\/immunitybio.com\/. Accessed 15 May 2024."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-024-02060-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-024-02060-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-024-02060-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T09:02:03Z","timestamp":1722330123000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-024-02060-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":28,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["2060"],"URL":"https:\/\/doi.org\/10.1007\/s40265-024-02060-1","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"5 June 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Susan J. Keam is a contracted employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability"}}]}}